Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Hematol Oncol Clin North Am. 2020 Apr;34(2):357-367. doi: 10.1016/j.hoc.2019.11.006. Epub 2020 Jan 18.
The acquisition of mutations in hematologic stem cells (clonal hematopoiesis) is common with normal aging and can be identified as an incidental finding through clinical genetic testing. Clonal hematopoiesis is associated with a heightened risk of developing hematologic neoplasms (especially myeloid) and accelerated atherosclerotic cardiovascular disease. This article discusses a multidisciplinary clinical approach to the management of patients with clonal hematopoiesis. Key areas of research needed to establish evidence-based clinical care guidelines and intervention strategies for individuals with clonal hematopoiesis are discussed.
血液干细胞(克隆性造血)突变的获得在正常衰老中很常见,可通过临床基因检测偶然发现。克隆性造血与发生血液系统肿瘤(尤其是髓系肿瘤)和加速动脉粥样硬化性心血管疾病的风险增加相关。本文讨论了克隆性造血患者管理的多学科临床方法。还讨论了为克隆性造血患者制定基于证据的临床护理指南和干预策略所需的关键研究领域。